An oral Alzheimer’s drug has shown promise in a Phase 2a trial, with results indicating it can reduce neuroinflammation in patients. The drug, called NTRX-07, targets the CB2 receptor, which is found on immune cells in the brain. By activating this receptor, the drug can reduce inflammation and promote a healthier environment in the brain.
The trial, conducted by NeuroTherapia, Inc., involved 48 adults with mild cognitive impairment or mild-to-moderate Alzheimer’s disease. The results showed that the drug was safe and well-tolerated, with no serious adverse events reported.
The trial included a set of exploratory biomarker and neuroimaging endpoints. The results showed that NTRX-07 reduced levels of neurofilament light chain, a protein associated with neuronal damage.
Related: Ukraine dismantles Russian $1.5 million Starlink jammers
NTRX-07 is designed to interrupt the inflammatory process in the brain by activating the CB2 receptor. This receptor is found on immune cells called microglia, which play a key role in the development of neuroinflammation. By activating the CB2 receptor, NTRX-07 can reduce the production of pro-inflammatory chemicals and promote a healthier environment in the brain.
The CB2 receptor is a G protein-coupled receptor that belongs to the endocannabinoid system. It is found on microglia and other immune cells in the brain and is involved in the regulation of inflammation. NTRX-07 is a selective CB2 receptor agonist, which means that it specifically targets this receptor without affecting other receptors in the brain.
The results of the Phase 2a trial suggest that NTRX-07 may have potential as a treatment for Alzheimer’s disease. The drug’s ability to reduce neuroinflammation and promote a healthier environment in the brain could make it a useful addition to existing treatments. Additionally, the fact that NTRX-07 is an oral pill, rather than an intravenous infusion, could make it more convenient for patients to use.
The potential implications of NTRX-07 extend beyond Alzheimer’s disease. The CB2 receptor is also involved in other neurological conditions, such as ALS, multiple sclerosis, and Parkinson’s disease. If NTRX-07 is shown to be effective in reducing neuroinflammation in these conditions, it could have a major impact on the treatment of these diseases.
Related: Fatal Fury Tournament Begins in Paris
NeuroTherapia has not yet announced a timeline for the next phase of clinical trials for NTRX-07. However, the company has indicated that the results of the Phase 2a trial will guide the design of the next trial, including the selection of patients, treatment duration, and endpoints. The fact that NTRX-07 has shown promise in reducing neuroinflammation suggests that it may be a useful treatment for Alzheimer’s disease, and further research is needed to fully explore its potential.
NTRX-07 is still an experimental compound, and replication in a larger, longer, adequately powered trial is required before any claims about disease modification can be made. The results have been presented at the Alzheimer’s Association International Conference in London.
They will use the results to guide the design of the next trial.